`
`S| POP Od4 $,42}ULd a19va
`
`
`
`(qw/6w ¢z)
`ys
`
`(Uo}y29fU] 1H @U|ysnwepUEq)
`OZdVu138 8
`
`Au XY
`aluays
`
`
`[eA BSOC-HININ=SZ-L2S-292h JON
`
`
`Mult+DoseVial
`NDC 42367-521-25
` Multi-Dose Vial
`Storein refrigerator, 2 to 8°C
`NDC 42367-521-25
`Cytotoxic Agent—Use caution during
`(36 to 46°F)
`Rx Only
`Sterile
`Rx Only
`handling and preparation. Use of gloves|Sterile
`Retainin original carton until
`and safety glasses is recommended
`time of use to protect from light.
`to avoid exposure. See insert for details.
`
`® BELRAPZO’
`(bendamustine HCI injection)
`100 mg/4 mL
`PAM Te8)
`
`For Intravenous Infusion Only
`Must dilute required dose ina
`500 ml infusion bag of 0,9% Sodium
`Chloride Injection or 2.5% Dextrose/
`0,45% Sodium Chloride Injection
`prior to administration.
`Marketed by:
`Eagle Pharmaceuticals, Inc.
`Woodcliff Lake, NU 07677
`ProductofItaly
`
`Usual Dosage: See prescribing
`information for dosing and dilution
`information.
`
`Each mLcontains 25 mg
`bendamustine hydrochloride, USP,
`0.1 mL propylene glycol, USP, 5 mg
`monothioglycerol, NF in polyethylene
`glycol 400, NF, sodium hydroxide, NF
`and waterfor injection, USP to adjust
`the pH of polyethylene glycol 400.
`
`® BELRAPZO
`(bendamustine HCI injection)
`Ee
`(25 mg/mL)
`
`For Intravenous Infusion Only
`Must dilute required dose in a
`500 ml infusion bag of 0.9% Sodium
`Chloride Injection or 2.5% Dextrose/
`0.45% Sodium Chloride Injection
`prior to administration.
`
`Iss. 11/2021
`
`WWL6'L9
`wGLEVTC
`WW9}"2S/
`wGZ8L9
`
`|
`
`WUWLQ"LSL
`uZ896'S
`
`|
`
`WWZ6'PE
`uGLE'L
`
`| wwze've
`wGLE"L
`
`|
`
`|
`
`(b) (4)
`
`
`
`
`
`I
`
`5.9687"
`151.61mm
`
`]
`
`|
`
`1.375"
`34.92mm |
`
`1.375"
`34.92mm
`
`]
`
`6.1875"
`157.16mm
`2.4375"
`61.91mm
`
`
`
`(b) (4)
`
`|
`
`5.9687"
`151.61mm
`
`|
`
`|
`
`1.375"
`34.92mm |
`
`1.375"
`34.92mm
`
`|
`
`a19Va
`
`
`
`
`
`
`
`Tw ¢/Gw oo
`(U0}}99fu) [)H @U;ysnwepUed)
`OZdVu1348 i@
`UO XY
`SUBS
`
`PIA 8sog-ynW=SZ 2S-29E7p JON
`
`
`NDC 42367-521-25—Multi-Dose Vial
`Store in refrigerator, 2 to 8°C
`NDC 42367-521-25 Mult#Dose Vial|Cytotoxic Agent—Use caution during
`
`Sterile
`Rx Only
`(36 to 46°F)
`Sterile Rx Only}handling and preparation. Use of gloves
`
`Retain in original carton until
`and safety glasses is recommended
`time of use to protectfrom light.
`to avoid exposure. See insert for details.
`
`6.1875"
`157.16mm
`2.4375"
`61.91mm
`
`® BELRAPZO’
`(bendamustine HCI injection)
`ete
`(25 mg/mL)
`
`For Intravenous Infusion Only
`Must dilute required dose ina
`500 mL infusion bag of 0.9% Sodium
`Chloride Injection or 2.5% Dextrose/
`0,45% Sodium Chloride Injection
`prior to administration.
`Marketed by:
`Eagle Pharmaceuticals, Inc.
`Woodcliff Lake, NJ 07677
`Product ofIndia
`GUJ/DRUGS/G/28/1304 EA SLE
`
`Usual Dosage: See prescribing
`information for dosing and dilution
`information,
`
`Each mL contains 25 mg
`bendamustine hydrochloride, USP.
`0.1 mL propyleneglycol, USP, 5 mg
`monothioglycerol, NF in polyethylene
`glycol 400, NF, sodium hydroxide, NF
`and waterfor injection, USP to adjust
`the pHof polyethyleneglycol 400.
`
`® BELRAPZO
`(bendamustine HCI injection)
`ete
`PAM Te8}
`
`For Intravenous Infusion Only
`Must dilute required dose ina
`500 mL infusion bag of 0.9% Sodium
`Chloride Injection or 2.5% Dextrose/
`0,45% Sodium Chloride Injection
`prior to administration.
`
`Iss. 11/2021
`
`Printer’s FPO code is
`variable and unique
`
`
`
`
`
`|
`
`5.9687"
`151.61mm
`
`l
`
`|
`
`1.375"
`34.92mm T
`
`1.375"
`34.92mm
`
`|
`
`6.1875"
`157.16mm
`2.4375"
`61.91mm
`
`
`
`Ramesh
`Raghavachari
`
`Digitally signed by Ramesh Raghavachari
`Date: 6/02/2022 03:20:31PM
`GUID: 502d0913000029f375128b0de8c50020
`
`(
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
